profit from every $100 of sales.
$0$100
Amicus Therapeutics
We have no price for Amicus Therapeutics since 27 April 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$14.49+0.00% today
+74.6% since Oct 10, 25
1-year low $8.041-year high $14.49
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Amicus Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $329 million in 2022 to $634 million in 2025, with -$27.1 million of profit last year.
SalesProfit
Amicus Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Amicus Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Amicus Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 329 | 399 | 528 | 634 | |
| 291 | 362 | 475 | 561 | |
| -204 | -73 | 34 | 34 | |
| -200 | -92 | 29 | 54 | |
| -237 | -152 | -56 | -27 | |
| -0.82 | -0.51 | -0.18 | – | |
| 88.3% | 90.7% | 90.0% | 88.5% | |
| -62.1% | -18.4% | 6.4% | 5.4% | |
| -71.9% | -38.0% | -10.6% | -4.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 724 | 778 | 785 | 950 |
| Cash | 149 | 247 | 214 | 214 |
| Total debt | 452 | 445 | 444 | 442 |
| Total liabilities | 601 | 618 | 591 | 676 |
| 123 | 160 | 194 | 274 | |
| 289 | 295 | 304 | – | |
| -28.1% | -13.0% | 2.6% | 5.1% | |
| -192.3% | -94.6% | -28.9% | -9.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -167 | -69 | -34 | 33 | |
| 4 | 7 | 4 | 3 | |
| -170 | -77 | -37 | 30 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 77 | 86 | 85 | 87 |
Valuation
- –
- –
- –
- –
- 7.2×
- 152.4×
- 88.8×
- 0.7%
- -0.6%
- –
Profitability
- 88.5%
- 5.4%
- -4.3%
- –
- –
- –
- –
- –
- –
- –
Growth
- +24.4%
- –
- –
- –
- –
Financial health
- –
- –
- –
- –
- –
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 41%of 872
Top 24%of 867
Bottom 45%of 986
What analysts expect
- Average price target
- $14.50
- Range
- $14.50 – $14.50
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Feb 20, 2026 | 0.01 | 0.07 | −86.0% |
| Nov 4, 2025 | 0.17 | 0.12 | +41.7% |
| Jul 31, 2025 | 0.01 | 0.02 | −50.0% |
| May 1, 2025 | 0.03 | 0.08 | −62.5% |
| Feb 19, 2025 | 0.09 | 0.02 | +350.0% |
| Nov 6, 2024 | 0.10 | 0.08 | +25.0% |
| Aug 8, 2024 | 0.06 | 0.05 | +9.8% |
| May 9, 2024 | -0.02 | -0.06 | +66.7% |
News
Nvidia's $3 billion Meta bet reveals a 30-fold shiftYahoo Finance · Oct 29, 2026AI chip giant SK hynix posts seven-fold surge in quarterly operating profitYahoo Finance · Oct 28, 2026SK Hynix Shares Spike in Seoul as Q3 Profit Jumps More Than 7-Fold: Memory Giant Plans $75 Billion in Shareholder ReturnsYahoo Finance · Oct 28, 2026Google cuts quantum errors 40-fold in step toward practical useSeeking Alpha · Oct 18, 2026Micron beats on earnings and issues strong guidance as data center revenue jumps 11-foldCNBC · Sep 30, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
42No pass
Benjamin Graham
66Pass
Philip Fisher
52No pass
Peter Lynch
54No pass
Joel Greenblatt
69Pass
Charlie Munger
41No pass
Terry Smith
37No pass
Questions about Amicus Therapeutics
Is Amicus Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Amicus Therapeutics AI analysis
What does Amicus Therapeutics do?
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. It is in Biotechnology, based in Princeton, NJ, United States, with 511 employees.
Does Amicus Therapeutics pay a dividend?
No. Amicus Therapeutics does not pay a dividend at the moment.
Who are Amicus Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Amicus Therapeutics's.
Prices: daily closes to Apr 27, 2026. Fundamentals: company reports via invest-like data.